Immunotech Biopharm Ltd (IMMUNOTECH-B) released its Monthly Return for the period ended 30 September 2026, confirming a stable capital structure and continued compliance with Hong Kong public-float rules. Key disclosures are outlined below.

Authorised and Issued Share Capital • Authorised share capital stood unchanged at 5.00 billion ordinary shares, each with a par value of USD 0.001, representing total authorised capital of USD 5.00 million. • Issued share capital remained at 617.50 million shares, with no new shares issued and no treasury shares outstanding during the month. • Public float met the minimum 25% threshold required under Main Board Rule 13.32B.

Equity Incentive Schemes • Pre-IPO Share Option Scheme: 9.87 million options were outstanding and unexercised; no shares were issued against these options in September. • Post-IPO Share Option Scheme: No options are currently outstanding, while the scheme still allows issuance of up to 9.87 million shares in future grants. • Total proceeds from option exercises in September: HKD 0.

Convertible Bonds • RMB-denominated convertible bonds outstanding totaled RMB 270.00 million, unchanged month-on-month. • The bonds carry a conversion price of HKD 2.92 per share and are convertible into up to 102.88 million new shares; no conversions occurred during September.

Warrants, HDRs and Other Instruments • The company reported no warrants, Hong Kong depositary receipts, or other equity-linked instruments outstanding or transacted. • No share repurchases, cancellations, or redemptions were recorded.

Regulatory Compliance • The Board confirmed that all securities-related activities during the month complied with relevant Hong Kong listing rules and regulatory requirements.

The absence of share issuance, share buybacks, or convertible-bond conversions underscores Immunotech-B’s unchanged equity base through September 2026. Investors can monitor future filings for any movement in the sizeable option pool or potential conversions from the RMB 270 million bond.